Mediar Therapeutics
About Mediar Therapeutics
Mediar is developing therapeutics that target fibrotic mediators to neutralize myofibroblasts, the key cells responsible for collagen deposition and organ scarring in fibrosis. This approach aims to slow disease progression and promote tissue regeneration in patients suffering from fibrotic diseases.
```xml <problem> Fibrotic diseases lead to organ scarring and failure due to excessive collagen deposition by myofibroblasts. Current treatments often fail to address the root cause of fibrosis, leaving a significant unmet need for therapies that can halt disease progression and promote tissue regeneration. </problem> <solution> Mediar is developing antibody therapeutics that target fibrotic mediators, a class of proteins responsible for activating myofibroblasts. By neutralizing these mediators, Mediar's approach aims to disable myofibroblasts, the key cells driving collagen deposition and organ scarring in fibrotic diseases. This therapeutic strategy has the potential to slow or halt disease progression and enable tissue regeneration. Furthermore, fibrotic mediators are measurable in plasma and correlate with disease severity, offering opportunities for precision medicine approaches in treating patients with fibrosis. </solution> <features> - Antibody therapeutics designed to neutralize fibrotic mediators - Targets myofibroblast activation to reduce collagen deposition - Aims to slow or halt the progression of fibrotic diseases - Potential to promote tissue regeneration in affected organs - Fibrotic mediators serve as potential biomarkers for disease severity and treatment response </features> <target_audience> The primary target audience includes patients suffering from fibrotic diseases, as well as physicians and researchers specializing in pulmonology, hepatology, and other fields related to organ fibrosis. </target_audience> ```
What does Mediar Therapeutics do?
Mediar is developing therapeutics that target fibrotic mediators to neutralize myofibroblasts, the key cells responsible for collagen deposition and organ scarring in fibrosis. This approach aims to slow disease progression and promote tissue regeneration in patients suffering from fibrotic diseases.
Where is Mediar Therapeutics located?
Mediar Therapeutics is based in Cambridge, United Kingdom.
When was Mediar Therapeutics founded?
Mediar Therapeutics was founded in 2019.
How much funding has Mediar Therapeutics raised?
Mediar Therapeutics has raised 124600000.
- Location
- Cambridge, United Kingdom
- Founded
- 2019
- Funding
- 124600000
- Employees
- 46 employees
- Major Investors
- Sofinnova Partners, Novartis Venture Fund